Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents
Phase of Trial: Phase I/II
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Cabotegravir (Primary) ; Cabotegravir (Primary) ; Rilpivirine (Primary) ; Rilpivirine (Primary) ; Antiretrovirals
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms MOCHA
- 29 Apr 2019 Planned primary completion date changed from 1 Apr 2021 to 15 Apr 2021.
- 22 Mar 2019 Status changed from not yet recruiting to recruiting.
- 04 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Mar 2019.